136 related articles for article (PubMed ID: 12691319)
21. [Standards, Options and Recommendations (SOR) for tumor markers in breast cancer. SOR Working Group].
Basuyau JP; Blanc-Vincent MP; Bidart JM; Daver A; Deneux L; Eche N; Gory-Delabaere G; Pichon MF; Riedinger JM
Bull Cancer; 2000 Oct; 87(10):723-37. PubMed ID: 11084536
[TBL] [Abstract][Full Text] [Related]
22. [CA 125 assay in the extension assessment of newly diagnosed breast cancers: why and how?].
Laffont A; Goussot V; Berriolo-Riedinger A; Riedinger JM
Ann Biol Clin (Paris); 2018 Oct; 76(5):553-561. PubMed ID: 30154065
[TBL] [Abstract][Full Text] [Related]
23. Diagnostic value of CA 549 in pleural fluid. Comparison with CEA, CA 15.3 and CA 72.4.
Villena V; López-Encuentra A; Echave-Sustaeta J; Martín-Escribano P; Ortuño-de-Solo B; Estenoz-Alfaro J
Lung Cancer; 2003 Jun; 40(3):289-94. PubMed ID: 12781427
[TBL] [Abstract][Full Text] [Related]
24. Clinical value of CA 15-3, mucin-like carcinoma-associated antigen, tumor polypeptide antigen, and carcinoembryonic antigen in monitoring early breast cancer patients.
Pectasides D; Pavlidis N; Gogou L; Antoniou F; Nicolaides C; Tsikalakis D
Am J Clin Oncol; 1996 Oct; 19(5):459-64. PubMed ID: 8823487
[TBL] [Abstract][Full Text] [Related]
25. Prospective evaluation of tumor markers (c-erbB-2 oncoprotein, CEA and CA 15.3) in patients with locoregional breast cancer.
Molina R; Filella X; Zanon G; Pahisa J; Alicarte J; Munoz M; Farrus B; Ballesta AM
Anticancer Res; 2003; 23(2A):1043-50. PubMed ID: 12820345
[TBL] [Abstract][Full Text] [Related]
26. The value of the tumor marker CA 15-3 in diagnosing and monitoring breast cancer. A comparative study with carcinoembryonic antigen.
Safi F; Kohler I; Röttinger E; Beger H
Cancer; 1991 Aug; 68(3):574-82. PubMed ID: 2065278
[TBL] [Abstract][Full Text] [Related]
27. [Usefulness of CEA, CA 15-3 and CA 125 tumor markers in the differential diagnostics of peritoneal effusion].
Kiluk MS; Rółkowski R; Zawadzki RJ; Wojtukiewicz MZ
Pol Merkur Lekarski; 2002 Oct; 13(76):298-301. PubMed ID: 12557435
[TBL] [Abstract][Full Text] [Related]
28. Clinical utility of CEA, CA 19-9, and CA 72-4 in the follow-up of patients with resectable gastric cancer.
Marrelli D; Pinto E; De Stefano A; Farnetani M; Garosi L; Roviello F
Am J Surg; 2001 Jan; 181(1):16-9. PubMed ID: 11248169
[TBL] [Abstract][Full Text] [Related]
29. Predictive value of CEA and CA 15-3 in the follow up of invasive breast cancer.
Sütterlin M; Bussen S; Trott S; Caffier H
Anticancer Res; 1999; 19(4A):2567-70. PubMed ID: 10470196
[TBL] [Abstract][Full Text] [Related]
30. Prognostic significance of serum Her2/neu, BCL2, CA15-3 and CEA in breast cancer patients: a short follow-up.
Samy N; Ragab HM; El Maksoud NA; Shaalan M
Cancer Biomark; 2010; 6(2):63-72. PubMed ID: 20571232
[TBL] [Abstract][Full Text] [Related]
31. The diagnostic value of serum tumor markers CEA, CA19-9, CA125, CA15-3, and TPS in metastatic breast cancer.
Wang W; Xu X; Tian B; Wang Y; Du L; Sun T; Shi Y; Zhao X; Jing J
Clin Chim Acta; 2017 Jul; 470():51-55. PubMed ID: 28457854
[TBL] [Abstract][Full Text] [Related]
32. [CA 15-3 and CEA as tumor markers in the diagnosis of the recurrence of breast cancer].
Engel K; Schmid H; Hanke J; Kaufmann M; Müller A
Geburtshilfe Frauenheilkd; 1988 May; 48(5):309-12. PubMed ID: 3165077
[TBL] [Abstract][Full Text] [Related]
33. Preoperative CA 15-3 and CEA serum levels as predictor for breast cancer outcomes.
Park BW; Oh JW; Kim JH; Park SH; Kim KS; Kim JH; Lee KS
Ann Oncol; 2008 Apr; 19(4):675-81. PubMed ID: 18037623
[TBL] [Abstract][Full Text] [Related]
34. [Tumor markers in breast cancer: on the diagnostic value of serum determinations in clinical freedom from tumor and manifest disease].
Günczler P; Ogris E; Maca S; Danmayr E
Onkologie; 1989 Oct; 12(5):209-14. PubMed ID: 2685686
[TBL] [Abstract][Full Text] [Related]
35. Sensitivity of monoclonal antibodies to carcinoembryonic antigen, tissue polypeptide antigen, alpha-fetoprotein, carbohydrate antigen 50, and carbohydrate antigen 19-9 in the diagnosis of colorectal adenocarcinoma.
Alvarez JA; Marín J; Jover JM; Fernández R; Fradejas J; Moreno M
Dis Colon Rectum; 1995 May; 38(5):535-42. PubMed ID: 7537651
[TBL] [Abstract][Full Text] [Related]
36. Significance of serum carcinoembryonic antigen and CA 15-3 in monitoring advanced breast cancer patients treated with systemic therapy: a large-scale retrospective study.
Kurebayashi J; Yamamoto Y; Tanaka K; Kohno N; Kurosumi M; Moriya T; Nishimura R; Ogawa Y; Taguchi T;
Breast Cancer; 2003; 10(1):38-44. PubMed ID: 12525762
[TBL] [Abstract][Full Text] [Related]
37. Does serum CA19-9 play a practical role in the management of patients with colorectal cancer?
Morita S; Nomura T; Fukushima Y; Morimoto T; Hiraoka N; Shibata N
Dis Colon Rectum; 2004 Feb; 47(2):227-32. PubMed ID: 15043294
[TBL] [Abstract][Full Text] [Related]
38. Use of serial carcinoembryonic antigen and CA 15.3 assays in detecting relapses in breast cancer patients.
Molina R; Zanón G; Filella X; Moreno F; Jo J; Daniels M; Latre ML; Giménez N; Pahisa J; Velasco M
Breast Cancer Res Treat; 1995; 36(1):41-8. PubMed ID: 7579505
[TBL] [Abstract][Full Text] [Related]
39. CEA, CA 15-3, and TPS as Prognostic Factors in the Follow-up Monitoring of Patients After Radical Surgery for Breast Cancer.
Svobodova S; Kucera R; Fiala O; Karlikova M; Narsanska A; Zedníková I; Treska V; Slouka D; Rousarova M; Topolcan O; Finek J
Anticancer Res; 2018 Jan; 38(1):465-469. PubMed ID: 29277810
[TBL] [Abstract][Full Text] [Related]
40. Clinical value of CEA for detection of distant metastases in newly diagnosed breast cancer: comparison with CA 15-3.
Maccio G; Goussot V; Berriolo-Riedinger A; Riedinger JM
Ann Biol Clin (Paris); 2017 Aug; 75(4):431-441. PubMed ID: 28751288
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
